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Abstract
A convenient liquid chromatography-tandem mass
spectrometry method for the quantification of the tri-
azole antifungal agent voriconazole in plasma sam-
ples is described. Fenbuconazole is used as an
internal standard. After protein precipitation, auto-
mated solid-phase extraction is applied. Electrospray
ionization in the positive mode is used and the follow-
ing mass transitions are recorded: voriconazole,
350™127; and fenbuconazol, 337™125. The analyti-
cal run time is 4 min. The response was linear from
78 to 5000 mg/L. The total coefficient of variation
(ns16) was 12.6% for a low-concentration pool
(143 mg/L), 4.7% for a medium-concentration pool
(419 mg/L), and 5.0% for a high-concentration pool
(4304 mg/L). The method is proposed for future inves-
tigations that should be performed to test the hypo-
thesis that therapeutic drug monitoring of voricon-
azole is clinically useful.
Keywords: liquid chromatography-tandem mass
spectrometry; solid phase extraction; therapeutic
drug monitoring; voriconazole.
Introduction
Voriconazole wUK-109,496; Vfend, Pfizer (1)x is a
relatively new triazole antimycotic agent that was
approved in the EU in 2002 for the treatment of inva-
sive aspergillosis and recently for first-line therapy for
invasive candidiasis. Voriconazole is available for
both intravenous and oral administration. The drug is
extensively metabolized by the hepatic cytochrome
P450 (CYP) enzymes, mainly by the isoenzymes
CYP2C19, CYP2C9, and CYP3A4 (2, 3). Due to this met-
abolic pathway, voriconazole is prone to interaction
with a very large number of drugs; compounds or
conditions which induce the mentioned CYP450 iso-
enzymes can result in decreased voriconazole plasma
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concentrations, whereas substrates of these enzymes
can lead to increased voriconazole levels by compe-
titive inhibition. Genetic polymorphisms of CYP450
isoenzymes (4), particularly of CYP2C19, may also
have an impact on the metabolization and conse-
quently the bioavailability of voriconazole. Voricona-
zole is characterized by non-linear pharmacokinetics
in all species studied (5). In the case of oral applica-
tion, resorption of the drug is questionable if muco-
sitis due to antineoplastic therapy or graft-versus-host
disease is suspected. Given this substantial inter- and
intra-individual variability in resorption and metabo-
lization, resulting in a wide range of trough plasma
concentrations (6–8), voriconazole doubtlessly repre-
sents a candidate for individualization of dosage
based on drug concentrations in blood (therapeutic
drug monitoring).
Itraconazole, another triazole antimycotic drug that
is now widely used for the prevention of invasive fun-
gal infections in hemato-oncological patients, is also
extensively metabolized by CYP450 enzymes and con-
sequently a variety of drug interactions is observed;
the usefulness of therapeutic monitoring of itracona-
zole is now widely accepted and justified by consis-
tent data (9). In contrast, the potential benefit of
therapeutic drug monitoring of voriconazole has not
been studied conclusively so far. Data reported by
Denning et al. (6) are consistent with a voriconazole
concentration of 250 mg/L as a threshold for thera-
peutic efficacy in invasive aspergillosis. Furthermore,
there is concern about hepatotoxicity associated with
voriconazole concentrations above 6000 mg/L (10).
These preliminary data doubtlessly warrant con-
trolled prospective large-scale investigations on the
usefulness of target concentration-based voriconazole
treatment. For respective studies and potential future
application of voriconazole measurement in a routine
setting, a specific and streamlined analytical method
is of essential importance. We describe here a con-
venient assay based on the innovative technology of
liquid chromatography-tandem mass spectrometry.
Materials and methods
Analytical procedure
Chemicals and calibration materials Methanol, acetonitrile,
and water were of HPLC grade (Baker, Deventer, The Nether-
lands). Voriconazole was donated by Pfizer Inc. (Groton, CN,
USA; Figure 1A). A stock solution (50 mg/L) was prepared in
acetonitrile. A stock calibrator (10,000 mg/L) was prepared by
spiking drug-free human plasma with the stock solution of
voriconazole. After overnight equilibration, working calibra-
tion materials with concentrations of 5000, 1000 and 100
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Figure 1 (A) Chemical structure of voriconazole. (B) Chemi-
cal structure of fenbuconazole, used as the internal standard
compound.
mg/L, respectively, were prepared by dilution of the stock
calibrator with drug-free plasma.
Separately, a voriconazole stock solution was diluted to
prepare quality control material with a concentration of
1000 mg/L.
For use as an internal standard, fenbuconazol (catalog no.
46096; Sigma, Deisenhofen, Germany) was used (Figure 1B).
A solution of this compound with a concentration of 1 mg/L
in acetonitrile was prepared (internal standard working solu-
tion, used for protein precipitation).
Instruments A Waters Alliance 2795 HPLC module (Waters,
Milford, MA, USA) was used. It was coupled to a Waters
Micromass Quattro LC Ultima Pt tandem mass spectrometry
system with a split ratio of approximately 1:10.
Sample preparation and chromatography Aliquots of 100
mL of patient plasma, calibrator or quality control samples,
respectively, were pipeted into 2-mL polypropylene cups,
then 200 mL of the internal standard working solution con-
taining 1 mg/L fenbuconazole was added. The samples were
vortex mixed and centrifuged for 12 min at 16,000=g in a
standard benchtop centrifuge. Stable protein pellets were
obtained and the clear supernatants were transferred to
HPLC vials.
For online solid-phase extraction, a Waters Oasis HLB
column (25 mm, 2.1=20 mm; Waters) was used in combi-
nation with a Rheodyne six-port high-pressure switching
valve (Rheodyne, Rohnert Park, CA, USA) installed in a
Waters 2795 separation module and controlled by Micro-
mass Masslynx 4.0 mass spectrometry software.
The automated extraction procedure consisted of three
steps. First, 5 mL of deproteinized sample was injected and
loaded onto the extraction column in valve position A (Figure
2). The mobile phase was water/methanol 95:5 (v/v) deli-
vered at a flow rate of 4.0 mL/min; potentially interfering
compounds were washed into the waste. In parallel, the
analytical column (LiCrospher 100 RP-18 end-capped,
125=4 mm, 5 mm; Merck, Darmstadt, Germany) was equili-
brated with 90% methanol/10% formic acid 0.1% (v/v) deliv-
ered at a flow rate of 0.85 mL/min. After 1 min the switching
valve was changed to position B. The extraction column was
then eluted in backflush mode onto the analytical column.
After 2 min, the valve was switched back to position A. Dur-
ing analytical chromatography into the mass spectrometer
in position A, the extraction column was washed with ace-
tonitrile/methanol 50:50 (v/v) at a flow rate of 4.0 mL/min for
1 min and subsequently re-equilibrated with water/methanol
95:5 (v/v). The extraction and analytical columns were main-
tained at 308C in a column oven. The retention times of vori-
conazole and fenbuconazole (internal standard) were
approximately 2.0 min after injection into the extraction col-
umn. The total analytical run time was 4 min.
Mass spectrometric conditions Electrospray atmospheric-
pressure ionization in the positive mode was used. The
source parameters were set to obtain the protonated quasi-
molecular ions of voriconazole and fenbuconazole (350 and
337 m/z, respectively). The following settings gave optimum
ion yield: capillary voltage, 3.9 kV; cone voltage, 57 V; source
temperature, 908C; desolvation temperature, 2808C; nitrogen
flow, approximately 550 L/h; and cone gas flow, approxi-
mately 75 L/h. The collision energy was 25 V with argon as
the collision gas. Under these conditions, several product
ions were generated from the analyte and the internal stan-
dard compound. For quantification purposes, the following
transitions were recorded: voriconazole, 350™127; and fen-
buconazole, 337™125. The dwell time for all multiple reac-
tion monitoring (MRM) traces was 0.3 s; the interchannel
delay and interscan delay were 0.15 s.
A representative chromatogram obtained from a pooled
plasma sample is given in Figure 3.
Assay validation
To study the recovery of the two-step extraction procedure
(protein precipitation followed by online solid-phase extrac-
tion), pure solutions of voriconazole and the internal stan-
dard fenbuconazole, respectively, dissolved in acetonitrile
(each 1000 mg/L) were analyzed directly by HPLC and tandem
mass spectrometry in triplicate; the peak areas of the two
respective MRM chromatograms were recorded. For com-
parison, drug-free plasma was spiked with the two com-
pounds to the same concentrations. These samples were
submitted to the entire method, including protein precipita-
tion and online solid-phase extraction, in triplicate. The peak
areas found for these spiked samples were compared with
those found for the pure solutions directly analyzed without
extraction. From the respective mean areas from both
experiments, the recovery rate was calculated.
To test the method for potential ion suppression effects,
five different plasma samples from patients not treated with
voriconazole were spiked to a concentration of 1000 mg/L
voriconazole and submitted to the entire method. For com-
parison, a pure solution of voriconazole at a concentration
of 1000 mg/L in acetonitrile/water (50:50 v/v) was analyzed in
the same way five times. The respective MRM peak areas for
voriconazole and fenbuconazole used as the internal stan-
dard were compared.
To study the linearity of the method, a drug-free plasma
sample was spiked to a concentration of 5000 mg/L with vori-
conazole; this sample was serially diluted 1:1 with drug-free
plasma in six steps. The concentration of voriconazole was
measured in all samples. The measured and expected con-
centrations were compared.
To study the imprecision of the method, plasma pools
were prepared from residual clinical samples from vorico-
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Figure 2 Column switching scheme used for online solid-phase extraction of voriconazole (W, waste; AC, analytical column).
Figure 3 Representative MRM chromatogram of voriconazole (350)126.6) and fenbuconazole (337)125) used as the internal
standard (concentration of voriconazole, 143 mg/L; the Y-axis represents the relative intensity of the signal with respect to the
base peak of the chromatogram).
nazole-treated patients at high, medium, and low concentra-
tion ranges (143, 419 and 4304 mg/L). These pools were
equilibrated overnight, aliquoted, and stored at y808C. In
four independent analytical series, each pool was analyzed
four times to calculate the respective intra-assay coefficients
of variation. A total coefficient of variation was calculated for
each pool from all 16 results obtained in the four analytical
series.
Results
A recovery rate of 96% for the entire extraction pro-
cedure, including manual deproteinization and auto-
mated online solid-phase extraction, was found. No
ion suppression was noted by comparison of the
MRM peak areas for voriconazole and the internal
standard, respectively, found in pure solution sam-
ples and human plasma samples spiked to the same
concentration; there was no significant difference in
the respective peak areas.
The results of the linearity investigation are given
in Table 1. Linear regression analysis of these data
revealed a coefficient of correlation of r2s0.999
between expected and observed voriconazole con-
centrations, confirming linearity of the assay for plas-
ma concentrations between 78 and 5000 mg/L.
In the imprecision study, the following mean con-
centrations were found, with the respective total coef-
ficient of variation (ns16): low pool, 143 mg/L, 12.6%
(intra-assay CV range 1.0–9.7%); medium pool,
419 mg/L, 4.7% (intra-assay CV range 0.7–3.8%); high
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Table 1 Results of the linearity investigation (serial dilution
of a spiked voriconazole sample with drug-free plasma).
Concentration, mg/L Accuracy, %
Expected Measured
5000 4865 97
2500 2561 102
1250 1303 104
612 623 102
306 287 94
153 163 107
75 78 104
0 0
pool, 4304 mg/L, 5.0% (intra-assay CV range
1.4–3.2%).
For the quality control sample with a spiked con-
centration of 1000 mg/L, a mean accuracy of 98.3%
was found in the analytical series performed during
method validation.
Discussion
In this article a convenient liquid chromatography-
tandem mass spectrometry method for the quantifi-
cation of plasma voriconazole concentrations is
described. The method uses automated online solid-
phase extraction with column switching and a poly-
meric extraction material; the related antimycotic
compound fenbuconazole is used as the internal stan-
dard. Assay validation demonstrated good analytical
performance of the method. Based on the imprecision
study, a concentration of 150 mg/L is recommended
as the lower limit of quantification of the method.
HPLC methods for the quantification of voricona-
zole using UV detection have been described previ-
ously (11–13). However, UV detection is a non-
specific technique. In particular, in patients with organ
failure and co-administration of multiple drugs – as
applies to most patients receiving voriconazole – the
risk of co-elution of unspecified endogenous or exog-
enous compounds together with voriconazole or a
respective internal standard substance in HPLC meth-
ods is substantial, and false results could be obtained
by applying UV detection. Since mass spectrometric
detection for HPLC has been developed as a routine
analytical technique in the clinical laboratory (14, 15),
such very specific methods should be applied when-
ever possible.
Very recently a method for serum voriconazole
measurement based on liquid chromatography-tan-
dem mass spectrometry has been published by Keevil
et al. (16). The assay described here, however, differs
essentially from this previous method, namely in the
mode of analyte extraction and in the internal stan-
dard used.
In the method described by Keevil et al. (16) a
simple variation of online solid-phase extraction is
applied that does not use a separate extraction col-
umn. In this method the analyte – bound to the ana-
lytical column after injection of precipitated sample –
is washed with only 300 mL of an aqueous solution
and subsequently eluted with methanol; the column
eluate is then transferred to the mass spectrometer
without solvent diversion. Using this ‘‘pre-chromato-
graphy’’ without column switching, the target analyte
is separated from residual matrix components, thus
reducing ion suppression effects. However, through-
out the whole analytical cycle, all matrix components
that remain after protein precipitation of the sample
enter the ion source and can cause contamination.
Therefore, the robustness of this method during
extended series in a routine setting is questionable.
In the method described here, the sample – after pro-
tein precipitation – is loaded onto a co-polymeric
extraction material packed in a separate extraction
column. This column is subsequently washed within
1 min with 5% methanol in water at a very high flow
rate, resulting in a washing volume of 4 mL. After col-
umn switching and backflush elution of the analyte
onto the separate analytical column, the extraction
column is washed with a high volume of an organic
solvent mix. Using this procedure, a very clean
extract is submitted to analytical chromatography and
finally transferred in split mode to the electrospray
ion source. The co-polymeric extraction material used
(Waters Oasis HLB) allows very high flow rates,
resulting in very efficient washing within a short time.
We have excellent experience with this extraction pro-
tocol, which has been applied for several years in the
analysis of immunosuppressants in whole blood and
itraconazole in plasma in our laboratory (17, 18). The
lifetime of the extraction and analytical columns is
several thousands of analyses. Minimal deposits are
found on the ion source components after several
thousands of analyses and the lifetime of the elec-
trospray capillary is very satisfactory. Online solid-
phase extraction after protein precipitation using
column switching and the Waters Oasis HLB material
is an extremely convenient, fast, and proven tech-
nique with generic applicability for lipophilic drugs.
The application of an appropriate internal standard
compound is of essential importance for reliable
and precise LC-MS methods. In conventional HPLC
methods, internal standardization is mainly necessary
to compensate for between-sample variations in the
efficacy of the extraction and imprecision of the HPLC
injector. In contrast, in liquid chromatography meth-
ods using atmospheric-pressure ionization, internal
standardization must moreover compensate for vari-
ations in the ionization efficacy from sample to
sample and within a series. The ion yield of atmos-
pheric-pressure ionization techniques typically undu-
lates within seconds or minutes and often shows
trends within hours. Variations in the ion yield can
differ substantially between different compounds. It is
essential and critical for the precision of an LC-MS
method that the short-term variation of the ionization
yield of a target analyte and the respective internal
standard due to source variables such as contamina-
tion is affected in a very similar manner. This is
ideally given by stable isotope-labeled internal stan-
dards; however, these are only available for a few
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drugs. In all other cases it is essential to find a com-
pound with a molecular structure that is very closely
related to that of the target analyte. Keevil et al. (16)
used ketoconazole as the internal standard. This com-
pound is also a triazole antimycotic drug; however, its
molecular structure is quite different from that of
voriconazole, as evident from the molecular mass
(voriconazole, 349; ketoconazole, 530). Instead of
ketoconazole, we use the agrochemical fenbucon-
azole for internal standardization; its molecular struc-
ture is very similar to that of voriconazole (Figure 1).
Assay validation data reported by Keevil et al. are in
close agreement with those found in our investiga-
tion. However, it must be assumed from the above-
mentioned considerations that the use of the very
closely related compound fenbuconazole instead of
the far less similar compound ketoconazole results in
superior long-term stability and robustness of an LC-
MS method for the quantification of voriconazole in
biological samples in a routine setting.
Principal considerations and preliminary epidemio-
logical data (6) point to the need for therapeutic drug
monitoring of voriconazole. Doubtlessly, further con-
trolled large-scale clinical studies are needed to clarify
the potential benefit of individualization of voricon-
azole treatment based on blood drug concentrations.
For further investigations, we propose the convenient
and rugged LC-MS method for voriconazole measure-
ment described in this report.
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